Matthew Nankivell

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

Sean Kehoe, Jane Hook, Matthew Nankivell et al. · The Lancet · 2015 · 1.4K citations

Gynecologic Surgery, Surgical Oncology, Gynecological Surgery +12

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

P. Mulvenna, Matthew Nankivell, Rachael Barton et al. · The Lancet · 2016 · 710 citations · Full text

Mismatch Repair Deficiency, Microsatellite Instability, and Survival

Elizabeth Smyth, Andrew Wotherspoon, Clare Peckitt et al. · JAMA Oncology · 2017 · 509 citations · Full text

Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial

Elizabeth Smyth, Matteo Fassan, David Cunningham et al. · Journal of Clinical Oncology · 2016 · 298 citations · Full text

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

Ignace Vergote, Corneel Coens, Matthew Nankivell et al. · The Lancet Oncology · 2018 · 290 citations · Full text

Surgical Oncology, Gynecological Surgery, Individual Patient Data +10